Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Do polyproline II helix associations modulate biomolecular condensates?

  • Mompeán, Miguel
  • Oroz, Javier
  • Laurents, Douglas V.
10 pags., 2 figs., 1 tab., Biomolecular condensates are microdroplets that form inside cells and serve to selectively concentrate proteins, RNAs and other molecules for a variety of physiological functions, but can contribute to cancer, neurodegenerative diseases and viral infections. The formation of these condensates is driven by weak, transient interactions between molecules. These weak associations can operate at the level of whole protein domains, elements of secondary structure or even moieties composed of just a few atoms. Different types of condensates do not generally combine to form larger microdroplets, suggesting that each uses a distinct class of attractive interactions. Here, we address whether polyproline II (PPII) helices mediate condensate formation. By combining with PPII-binding elements such as GYF, WW, profilin, SH3 or OCRE domains, PPII helices help form lipid rafts, nuclear speckles, P-body-like neuronal granules, enhancer complexes and other condensates. The number of PPII helical tracts or tandem PPII-binding domains can strongly influence condensate stability. Many PPII helices have a low content of proline residues, which hinders their identification. Recently, we characterized the NMR spectral properties of a Gly-rich, Pro-poor protein composed of six PPII helices. Based on those results, we predicted that many Gly-rich segments may form PPII helices and interact with PPII-binding domains. This prediction is being tested and could join the palette of verified interactions contributing to biomolecular condensate formation., JO is a Ramon y Cajal Fellow of the Spanish AEI- Ministry of Science and Innovation (RYC2018- 026042-I) and a Leonardo Fellow from the BBVA Foundation (Grant Number BBM-TRA-0203). MM is a Ramon y Cajal Fellow of the Spanish AEI-Ministry of Science and Innovation (RYC2019-026574-I) and a ‘La Caixa’ Foundation Junior Leader Fellow (LCR/ BQ/PR19/11700003). This study was supported by Grant BTC-PID2019-109306RB-I00 (DVL) from the Spanish Ministry of Science and Innovation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NLRP3 haploinsufficiency unmasks a compensatory NLRP1-NLRP3 interaction that drives accelerated aging in mice

  • Muela-Zarzuela, Inés
  • Alcocer-Gómez, Elisabet
  • Suarez-Rivero, Juan M.
  • Low, Evon
  • Ishaq, Abbas
  • Azkargorta, Mikel
  • Luque-Sierra, Amparo
  • Martin, Franz
  • Elortza, Félix
  • Astorga-Gamaza, Antonio
  • Antón, Rosa
  • Bali, Sofía
  • Tamargo-Azpilicueta, Joaquin
  • Guerra-Castellano, Alejandra
  • Díaz-Moreno, Irene
  • Joachimiak, Lukasz A.
  • Oroz, Javier
  • Ruiz-Cabello, Jesús
  • von Zglinicki, Thomas
  • Sanz, Alberto
  • Cordero, Mario D.
The NLRP3 inflammasome has been implicated in a wide range of human diseases, including cardiovascular, metabolic, neurodegenerative (such as Alzheimer's disease), and other age-related conditions. This has positioned NLRP3 as a promising pharmacological target. Numerous studies have shown that complete NLRP3 ablation can prevent or mitigate these diseases. However, total elimination of NLRP3 is not a feasible therapeutic strategy for the millions of patients affected by these degenerative disorders. Consequently, drug development efforts have focused on partial inhibition of NLRP3 using compounds that reduce its expression or activity. Paradoxically, although many studies have used Nlrp3 knockout mouse models, Nlrp3 haploinsufficient mice-more representative of the effects of pharmacological inhibition-are rarely included and remain poorly characterized. Here, we report the long-term effects of Nlrp3 haploinsufficiency during aging. Although no overt differences were observed in early life, by 16 months of age, Nlrp3 heterozygous mice exhibited signs of accelerated inflammatory aging, driven by compensatory overexpression of NLRP1. Mechanistic studies provide evidence of a previously unidentified interaction between NLRP1 and NLRP3, forming a hybrid inflammasome that drives NLRP1-mediated inflammatory overactivation when NLRP3 expression is reduced. Accordingly, anti-inflammatory treatment provided notable but moderate improvement of the inflammatory phenotype, whereas genetic inhibition of Nlrp1 more consistently reduced inflammation and extended health span. Our findings reveal a previously unidentified compensatory interaction between NLRP1 and NLRP3 and suggest that multiinflammasome inhibition may offer a more effective strategy for treating aging and age-related diseases., This study was supported by grant PI21/01656 from the Instituto de Salud Carlos III (Spain), grant EMC21_00033 from the EMERGIA programme of the Junta de Andalucía, and grant CNS2024-154939 from the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación. Funding for open access publication was provided by the Universidad Pablo de Olavide/CBUA. J.R.-C . is funded by grant PID2021-123238OB- I00 and PID2024-155807OB- C 21 funded by the MCIN/AEI and from the Fundación contra la Hipertensión Pulmonar (Project Empathy). I.D.-M. is funded by grant PID2024-157414NB- I00 funded by the MICIU/AEI/10.13039/501100011033 and by ERDF/EU, Ramon Areces Foundation (LEUCYTO-FRA2025- MAR), grant FPU22/01094 funded by MICIU/AEI/10.13039/501100011033 and by ESF+ to J.T.-A., and grant PTQ2024-013941 funded by MICIU/AEI/10.13039/501100011033 to A.G.-C . J.O. is supported by the grants PID2019-109276RA- I00 and PID2022-142382OB- I00 funded by MCIN/AEI/10.13039/501100011033 and by FEDER A way to make Europe and by donations from the Spanish and Mexican Ondine Associations. J.O. was a recipient of a Leonardo Grant from the Spanish BBVA Foundation (BBM_TRA_0203) and a Ramón y Cajal Fellow of the Spanish AEI-Ministry of Science and Innovation (RYC2018-026042- I funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Molecular mechanism for the synchronized electrostatic coacervation and co-aggregation of a-synuclein and tau

  • Gracia, Pablo
  • Polanco, David
  • Tarancón-Díez, Jorge
  • Serra, Ilenia
  • Bracci, Maruan
  • Oroz, Javier
  • Laurents, Douglas V.
  • García-Rubio, Inés
  • Cremades, Nunilo
Amyloid aggregation of α-synuclein (αS) is the hallmark of Parkinson’s disease and other synucleinopathies. Recently, Tau protein, generally associated with Alzheimer’s disease, has been linked to αS pathology and observed to co- localize in αS-rich disease inclusions, although the molecular mechanisms for the co-aggregation of both proteins remain elusive. We report here that αS phase-separates into liquid condensates by electrostatic complex coacerva- tion with positively charged polypeptides such as Tau. Condensates undergo either fast gelation or coalescence followed by slow amyloid aggregation depending on the affinity of αS for the poly-cation and the rate of valence exhaustion of the condensate network. By combining a set of advanced bio- physical techniques, we have been able to characterize αS/Tau liquid-liquid phase separation and identified key factors that lead to the formation of hetero-aggregates containing both proteins in the interior of the liquid protein condensates.